<DOC>
	<DOCNO>NCT00081926</DOCNO>
	<brief_summary>This study evaluate molecular response high dose Gleevec newly diagnose patient Chronic Myelogenous Leukemia ( CML ) Chronic Phase . This study evaluate ability Gleevec reduce amount abnormal protein occur patient CML . Patients eligible participate treat 18 month . This trial include male female patient 18 year old newly diagnose ( within 6 month ) CML .</brief_summary>
	<brief_title>Gleevec Trial Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Participants must meet following criterion : Male Female patient 18 year old . Patient diagnosis chronic myelogenous leukemia chronic phase Within 6 month initial diagnosis . Received treatment CML le 1 month prior study entry exception hydroxyurea and/or anagrelide . Late chronic phase , accelerate phase blastic phase Taking investigational agent within 28 day start study If sibling donor identify allogeneic bone marrow transplantation first line treatment . Another primary malignancy /cancer unless consider clinically significant require active intervention . If patient heart problem complication Pregnant breastfeeding female Severe and/or uncontrolled disease diabetes , chronic renal disease , etc . Chronic liver disease ( i.e. , chronic active hepatitis , cirrhosis ) . Diagnosis human immunodeficiency virus ( HIV ) infection . Received treatment CML longer 1 month prior study entry exception hydroxyurea and/or anagrelide . Patient previously receive radiotherapy great 25 % bone marrow . Patient major surgery within 4 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>CML</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>RIGHT Trial</keyword>
	<keyword>US177</keyword>
	<keyword>CSTI571</keyword>
</DOC>